CHF6795 / Chiesi - LARVOL DELTA

In Vitro Characterization of CHF6795, A New Potent and Selective P2X3 Inhibitor With Anti-tussive Properties (ATS 2025) - "Indeed, a first P2X2/3 inhibitor, gefapixant, has reached the market for the treatment of CC. CHF6795 is a new, highly effective, and selective P2X3 inhibitor being explored as an anti-tussive agent. It shows great promise due to its specific targeting, which should avoid any impact on taste perception."

Preclinical • Chronic Cough • Cough • Respiratory Diseases

First-in-Human Study of CHF 6795, an Oral Selective P2X3 Antagonist for Refractory Chronic Cough (ATS 2025) - "CHF6795 was rapidly absorbed and slowly eliminated in healthy participants. Systemic exposure generally increased dose-proportionally. No relevant food or sex effects on PK were noted."

P1 data • Chronic Cough • Cough • Immunology • Otorhinolaryngology • Respiratory Diseases • Vertigo • CST3

CHF6795 a Novel, Potent, and Selective Oral P2X3R Antagonist Showing Strong Anti-tussive Effect and No Taste Alteration in Preclinical Models (ATS 2025) - "Indeed, a first P2X2/3R antagonist, gefapixant, has reached the market for the treatment of CC. CHF6795 was selected as a drug candidate for the treatment of CC due to P2X3R selectivity, potency and efficacy in inducing an anticough effect without taste alteration at the effective doses. CHF6795 currently completed Ph1 study."

Preclinical • Chronic Cough • Cough • Respiratory Diseases